NASDAQ : INDP
Indaptus Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.09 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 474.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 9.56M | 10.49M | 8.11M | 8.76M | 8.59M | 5.21M |
| Research & Development | 5.22M | 9.34M | 7.25M | 7.62M | 6.32M | 2.52M |
| Operating Expenses | 14.77M | 19.83M | 15.37M | 16.38M | 14.91M | 7.73M |
| Operating Income | -14.77M | -19.83M | -15.37M | -16.38M | -14.91M | -7.73M |
| Other Non Operating Income (Expenses) | -650.86K | -1.02M | 343.72K | 955.00K | 588.11K | 17.72K |
| Pretax Income | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Net Income | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Net Income to Common | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Shares Outstanding (Basic) | 32.75M | 966.12K | 334.13K | 300.04K | 295.08K | 146.09K |
| Shares Outstanding (Diluted) | 32.75M | 966.12K | 334.13K | 300.04K | 295.08K | 146.09K |
| EPS (Basic) | -0.47 | -21.58 | -44.96 | -51.41 | -48.54 | -52.78 |
| EPS (Diluted) | -0.47 | -21.58 | -44.96 | -51.41 | -48.54 | -52.78 |
| Free Cash Flow | -14.70M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Free Cash Flow Per Share | -0.45 | -15.34 | -36.88 | -44.68 | -44.32 | -77.31 |
| EBITDA | -19.83M | -15.37M | -16.38M | -14.91M | -7.73M | |
| D&A For EBITDA | 735.00 | 735.00 | 1.28K | 1.78K | 1.40K | |
| EBIT | -14.77M | -19.83M | -15.37M | -16.38M | -14.91M | -7.73M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 7.55M | 8.51M | 5.79M | 13.36M | 9.63M | 39.13M |
| Short-Term Investments | 4.00M | 16.81M | ||||
| Cash & Short-Term Investments | 11.55M | 8.51M | 5.79M | 13.36M | 26.43M | 39.13M |
| Other Receivables | 21.06K | |||||
| Receivables | 21.06K | |||||
| Prepaid Expenses | 406.36K | 409.97K | 681.58K | 615.85K | 730.52K | 957.95K |
| Other Current Assets | 27.78K | 392.57K | 150.00K | 17.31K | 80.91K | 276.04K |
| Total Current Assets | 11.99M | 9.31M | 6.62M | 14.00M | 27.24M | 40.39M |
| Property, Plant & Equipment | 82.17K | 173.94K | 81.31K | 172.89K | ||
| Other Long-Term Assets | 638.25K | 754.73K | 738.25K | 16.48K | ||
| Total Assets | 11.99M | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Accounts Payable | 508.88K | 544.06K | 870.23K | 806.00K | 1.38M | 2.54M |
| Accrued Expenses | 106.55K | 5.61M | 2.44M | 1.87M | 1.97M | 1.97M |
| Current Portion of Leases | 84.16K | 101.70K | 80.49K | 96.47K | ||
| Total Current Liabilities | 615.43K | 6.16M | 3.39M | 2.77M | 3.43M | 4.60M |
| Long-Term Leases | 73.35K | 72.86K | ||||
| Total Liabilities | 615.43K | 6.16M | 3.39M | 2.85M | 3.43M | 4.68M |
| Common Stock | 1.33M | 21.67K | 4.29K | 84.01K | 84.01K | 82.59K |
| Additional Paid-In Capital | 95.66M | 84.41M | 64.38M | 57.41M | 54.44M | 51.49M |
| Retained Earnings | -85.62M | -81.29M | -60.44M | -45.42M | -29.99M | -15.67M |
| Comprehensive Income & Other | 96.43K | |||||
| Total Common Equity | 11.37M | 3.14M | 3.94M | 12.08M | 24.63M | 35.90M |
| Shareholders' Equity | 11.37M | 3.15M | 3.94M | 12.08M | 24.63M | 35.90M |
| Total Liabilities & Equity | 11.99M | 9.31M | 7.34M | 14.92M | 28.06M | 40.58M |
| Total Debt | 84.16K | 175.05K | 80.49K | 169.33K | ||
| Net Cash (Debt) | 11.55M | 8.51M | 5.70M | 13.19M | 26.35M | 38.96M |
| Net Cash Per Share | 0.35 | 8.81 | 17.07 | 43.95 | 89.31 | 266.70 |
| Filing Date Shares Outstanding | 133.24M | 2.24M | 515.33K | 304.96K | 300.04K | 294.95K |
| Total Common Shares Outstanding | 133.24M | 2.17M | 429.07K | 300.04K | 300.04K | 294.95K |
| Working Capital | 11.37M | 3.15M | 3.22M | 11.22M | 23.81M | 35.78M |
| Book Value Per Share | 0.09 | 1.45 | 9.19 | 40.25 | 82.09 | 121.71 |
| Tangible Book Value | 11.37M | 3.14M | 3.94M | 12.08M | 24.63M | 35.90M |
| Tangible Book Value Per Share | 0.09 | 1.45 | 9.19 | 40.25 | 82.09 | 121.71 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -15.42M | -20.85M | -15.02M | -15.42M | -14.32M | -7.71M |
| Depreciation & Amortization | 735.00 | 1.28K | 1.78K | 1.40K | ||
| Loss (Gain) From Sale of Assets | -24.16K | |||||
| Stock-Based Compensation | 1.10M | 1.36M | 2.31M | 2.97M | 2.96M | 1.51M |
| Other Operating Activities | 775.87K | 1.15M | -430.99K | -110.00K | ||
| Change in Accounts Payable | -1.36M | 2.85M | 474.06K | -680.52K | -1.15M | -4.24M |
| Change in Other Net Operating Assets | 213.00K | 665.30K | -81.80K | 162.45K | -425.59K | -854.15K |
| Operating Cash Flow | -14.70M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Capital Expenditures | -3.85K | |||||
| Sale of Property, Plant & Equipment | 172.56K | 451.60K | ||||
| Investment in Securities | -4.00M | 17.14M | -16.60M | |||
| Investing Cash Flow | -4.00M | 17.14M | -16.43M | 447.75K | ||
| Short-Term Debt Issued | 5.71M | |||||
| Total Debt Issued | 5.71M | |||||
| Net Debt Issued (Repaid) | 5.71M | |||||
| Issuance of Common Stock | 14.34M | 6.40M | 5.51M | 390.33K | ||
| Other Financing Activities | -249.39K | -569.47K | -762.70K | 47.95M | ||
| Financing Cash Flow | 20.09M | 17.54M | 4.75M | 48.34M | ||
| Net Cash Flow | 1.40M | 2.72M | -7.58M | 3.74M | -29.51M | 37.49M |
| Free Cash Flow | -14.70M | -14.82M | -12.32M | -13.41M | -13.08M | -11.29M |
| Free Cash Flow Per Share | -0.45 | -15.34 | -36.88 | -44.68 | -44.32 | -77.31 |
| Levered Free Cash Flow | -9.67M | -8.16M | -6.86M | -7.77M | -7.07M | -1.99M |
| Unlevered Free Cash Flow | -9.67M | -8.16M | -6.86M | -7.77M | -7.07M | -1.99M |
| Cash Income Tax Paid | 1.60K | 2.40K | 800.00 | |||
| Change in Working Capital | -1.15M | 3.51M | 392.25K | -518.07K | -1.58M | -5.09M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 474.57M | 5.10M | 10.12M | 14.79M | 12.18M | 46.70M |
| Enterprise Value | 463.01M | -721.07K | 2.84M | -981.94K | -16.18M | 4.80M |
| Last Close Price | 3.09 | 2.91 | 23.58 | 49.28 | 40.60 | 159.60 |
| PB Ratio | 36.20 | 1.62 | 2.56 | 1.22 | 0.49 | 1.30 |
| P/TBV Ratio | 41.73 | 1.62 | 2.56 | 1.22 | 0.49 | 1.30 |
| Debt / Equity Ratio | 0.02 | 0.01 | 0.00 | 0.01 | ||
| Net Debt / Equity Ratio | -1.02 | -2.70 | -1.45 | -1.09 | -1.07 | -1.08 |
| Net Debt / EBITDA Ratio | 0.43 | 0.37 | 0.81 | 1.77 | 5.04 | |
| Net Debt / FCF Ratio | 0.79 | 0.57 | 0.46 | 0.98 | 2.02 | 3.45 |
| Quick Ratio | 18.77 | 1.38 | 1.71 | 4.82 | 7.70 | 8.50 |
| Current Ratio | 19.48 | 1.51 | 1.95 | 5.04 | 7.93 | 8.77 |
| Return on Equity (ROE) | -318.04% | -587.59% | -187.53% | -84.04% | -47.32% | -43.25% |
| Return on Assets (ROA) | -98.08% | -148.91% | -86.28% | -47.62% | -27.15% | -22.81% |
| Return on Capital Employed (ROCE) | -129.90% | -629.30% | -389.50% | -134.80% | -60.50% | -21.50% |
| Earnings Yield | -15.24% | -409.13% | -148.48% | -104.31% | -117.58% | -16.51% |
| FCF Yield | -3.10% | -290.89% | -121.81% | -90.66% | -107.36% | -24.18% |
| Buyback Yield / Dilution | -7,142.37% | -189.14% | -11.36% | -1.68% | -101.98% | -110.35% |